Tobramycin inhalation - Pulmoflow

Drug Profile

Tobramycin inhalation - Pulmoflow

Alternative Names: Kitabis Pak

Latest Information Update: 03 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PARI Pharma GmbH; PulmoFlow
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 21 Jul 2015 The US FDA lists KitabisTM Pak on the Prefered Drug List
  • 16 Mar 2015 The US FDA lists Kitabis™ Pak in the Orange Book as a therapeutic equivalent of TOBI® (tobramycin inhalation solution, USP)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top